rhigf1  (Ipsen Group)

Journal: eLife

Article Title: A novel human pluripotent stem cell gene activation system identifies IGFBP2 as a mediator in the production of haematopoietic progenitors in vitro

doi: 10.7554/eLife.94884

Figure Lengend Snippet:

Article Snippet: Peptide, recombinant protein , rhIGF1 , Peprotech , 100-11-100uG , 25 ng/ml.

Techniques: Cloning, Plasmid Preparation, Recombinant, Expressing, Sequencing, Flow Cytometry, Amplification

Journal: Biology of Sex Differences

Article Title: Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments

doi: 10.1186/s13293-024-00603-5

Figure Lengend Snippet: Hormone concentrations in the plasma and pituitary gland of Pappa2 ko/ko and Pappa2 wt/wt mice (males and females) in adulthood. Concentrations of total IGF1 ( A ), IGFBP5 ( B ) and GH in plasma ( C ), and GH in pituitary gland ( D ) are represented as mean ± S.E.M ( n = 8–10 per experimental group). Two-way ANOVA and Tukey-corrected tests: * / *** p < 0.05/0.001 versus respective wt/wt males and females; ### p < 0.001 versus respective wt/wt and ko/ko males

Article Snippet: Recombinant human GH protein (rhGH; cat no: ABIN803848; antibodies-online GmbH, Aachen, Germany), recombinant human IGF1 protein (rhIGF1; cat. no: 100 − 11; PeproTech, Inc., Rocky Hill, NJ, USA), and recombinant human PAPP-A2 protein (rhPAPP-A2; cat. no: abx068418; Abbexa LTD, Cambridge; UK) were dissolved in sterile saline (0.9% NaCl).

Techniques: Clinical Proteomics

Journal: Biology of Sex Differences

Article Title: Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments

doi: 10.1186/s13293-024-00603-5

Figure Lengend Snippet: IGF1 system gene expression in the hypothalamus, the pituitary gland and the liver of Pappa2 ko/ko and Pappa2 wt/wt mice (males and females) in adulthood. Hypothalamus: relative Pappa2 ( A ), Ghrh ( B ), Ghih-Sst ( C ), Igf1 ( D ), Igf1r ( E ), Igfbp3 ( F ), Igfbp5 ( G ), Igfals ( H ) and Stc1 ( I ) mRNA levels. Pituitary gland: relative Pappa2 ( J ), Gh ( K ), Ghrhr ( L ), Igf1 ( M ), Igf1r ( N ), Igfbp3 ( O ), Igfbp5 ( P ), Igfals ( Q ) and Stc1 ( R ) mRNA levels. Liver: relative Ghr ( S ), Igf1 ( T ), Igf1r ( U ), Igf2 ( V ), Igfbp3 ( W ), Igfbp5 ( X ), Igfals ( Y ) and Stc1 ( Z ) mRNA levels. Data are represented as mean ± S.E.M ( n = 8–10 per experimental group). See Table for additional information. Two-way ANOVA and Tukey-corrected tests: * / *** p < 0.05/0.001 versus respective wt/wt males and females; ##/### p < 0.01/0.001 versus respective wt/wt and ko/ko males

Article Snippet: Recombinant human GH protein (rhGH; cat no: ABIN803848; antibodies-online GmbH, Aachen, Germany), recombinant human IGF1 protein (rhIGF1; cat. no: 100 − 11; PeproTech, Inc., Rocky Hill, NJ, USA), and recombinant human PAPP-A2 protein (rhPAPP-A2; cat. no: abx068418; Abbexa LTD, Cambridge; UK) were dissolved in sterile saline (0.9% NaCl).

Techniques: Gene Expression

Journal: Biology of Sex Differences

Article Title: Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments

doi: 10.1186/s13293-024-00603-5

Figure Lengend Snippet: Key sensors of IGF1 signaling pathways in the hypothalamus, the pituitary gland and the liver of Pappa2 ko/ko and Pappa2 wt/wt mice (males and females) in adulthood. Hypothalamus: phosphorylated forms of PI3K ( A ), AKT ( B ), mTOR ( C ), GSK3β ( D ), ERK1 ( E ), ERK2 ( F ), AMPKα ( G ) and GS ( H ). Pituitary gland: phosphorylated forms of GSK3β ( J ), AMPKα ( K ), ERK1 ( L ) and ERK2 ( M ). Liver: phosphorylated forms of PI3K ( O ), AKT ( P ), mTOR ( Q ), GSK3β ( R ), ERK1 ( S ), ERK2 ( T ), AMPKα ( U ) and GS ( V ). Data are represented as mean ± S.E.M ( n = 6 per experimental group). Representative immunoblots ( I, N and W ) are also shown. See Table and Figures - for additional information. Two-way ANOVA and Tukey-corrected tests: * / ** / *** p < 0.05/0.01/0.001 versus respective wt/wt males and females; #/##/### p < 0.05/0.01/0.001 versus respective wt/wt and ko/ko males

Article Snippet: Recombinant human GH protein (rhGH; cat no: ABIN803848; antibodies-online GmbH, Aachen, Germany), recombinant human IGF1 protein (rhIGF1; cat. no: 100 − 11; PeproTech, Inc., Rocky Hill, NJ, USA), and recombinant human PAPP-A2 protein (rhPAPP-A2; cat. no: abx068418; Abbexa LTD, Cambridge; UK) were dissolved in sterile saline (0.9% NaCl).

Techniques: Protein-Protein interactions, Western Blot

Journal: Biology of Sex Differences

Article Title: Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments

doi: 10.1186/s13293-024-00603-5

Figure Lengend Snippet: Experimental design ( A ) and schematic diagram ( B ) of the analysis of circulating hormone concentrations, and liver IGF1 system gene expression in Pappa2 ko/ko and Pappa2 wt/wt mice (males and females) treated with rhGH, rhIGF1 and rhPAPP-A2 for 30 days, from PND5 to PND35. Concentrations of total IGF1 ( C ) and IGFBP5 ( D ) in plasma, and relative Igf1 ( E ), Ghr ( F ), Igf1r ( G ), Igfbp3 ( H ), Igfbp5 ( I ), Igfals ( J ), Stc1 ( K ) and Stc1 ( L ) mRNA levels are represented as mean ± S.E.M ( n = 8–10 per experimental group). See Table for additional information. Two-way ANOVA and Tukey-corrected tests: */**/*** p < 0.05/0.01/0.001 versus respective saline-treated males and females; #/##/### p < 0.05/0.01/0.001 versus respective wt/wt males and females

Article Snippet: Recombinant human GH protein (rhGH; cat no: ABIN803848; antibodies-online GmbH, Aachen, Germany), recombinant human IGF1 protein (rhIGF1; cat. no: 100 − 11; PeproTech, Inc., Rocky Hill, NJ, USA), and recombinant human PAPP-A2 protein (rhPAPP-A2; cat. no: abx068418; Abbexa LTD, Cambridge; UK) were dissolved in sterile saline (0.9% NaCl).

Techniques: Gene Expression, Clinical Proteomics, Saline

Journal: Biology of Sex Differences

Article Title: Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments

doi: 10.1186/s13293-024-00603-5

Figure Lengend Snippet: Experimental design ( A ) and schematic diagram ( B ) of the analysis of key regulators of IGF1 signaling pathways in the liver of Pappa2 ko/ko and Pappa2 wt/wt mice (males and females) treated with rhGH, rhIGF1 and rhPAPP-A2 for 30 days, from PND5 to PND35. Phosphorylated forms of IRS1 ( C ), PI3K ( D ), AKT ( E ), mTOR ( F ), GSK3β ( G ), ERK2 ( H ) and AMPKα ( I ) are represented as mean ± S.E.M ( n = 6 per experimental group). Representative immunoblots ( J ) are also shown. See Table and Figures and S6 for additional information. Two-way ANOVA and Tukey-corrected tests: */**/*** p < 0.05/0.01/0.001 versus respective saline-treated males and females; #/## p < 0.05/0.01 versus respective wt/wt males and females

Article Snippet: Recombinant human GH protein (rhGH; cat no: ABIN803848; antibodies-online GmbH, Aachen, Germany), recombinant human IGF1 protein (rhIGF1; cat. no: 100 − 11; PeproTech, Inc., Rocky Hill, NJ, USA), and recombinant human PAPP-A2 protein (rhPAPP-A2; cat. no: abx068418; Abbexa LTD, Cambridge; UK) were dissolved in sterile saline (0.9% NaCl).

Techniques: Protein-Protein interactions, Western Blot, Saline

Journal: Biology of Sex Differences

Article Title: Sex-based differences in growth-related IGF1 signaling in response to PAPP-A2 deficiency: comparative effects of rhGH, rhIGF1 and rhPAPP-A2 treatments

doi: 10.1186/s13293-024-00603-5

Figure Lengend Snippet: ( A ) Schematic diagrams summarizing the alterations in the hypothalamus-pituitary-liver axis that result in decreased body and femur length in Pappa2 ko/ko mice (males and females) in adulthood. Increased and decreased levels are represented by a blue arrow for males and a red arrow for females. The effect of genotype is indicated by an asterisk (*). Reduced body and femur length of Pappa2 ko/ko mice and female-specific increased expressions of components of IGF1 binary/ternary complexes (IGF1 and IGFBP5 in plasma, Igfbp5 in hypothalamus, and Igfbp3 and Igfals in liver) could be consistent with reduced IGF1 availability and signaling in target tissues. Sex-specific modulation of key sensors of IGF1 signaling pathways (phosphorylation of AKT, mTOR, GSK3β and ERK1/2 in the female hypothalamus, phosphorylation of GSK3β and ERK1/2 in the male pituitary gland, and phosphorylation of PI3K and AMPKα in the female liver) may be relevant to explain growth impairment through a dysregulated IGF1 system due to PAPP-A2 deficiency. ( B ) Schematic diagrams summarizing changes in IGF1 ternary complex components and IGF1 signaling pathways that result in increased body and/or femur length after the pharmacological administration of rhGH, rhIGF1 and rhPAPP-A2 for 30 days (PND5-35) in Pappa2 ko/ko mice (males and females) at puberty onset. Increased and decreased levels are represented by a blue arrow for males and a red arrow for females. The effect of treatment is indicated by an asterisk (*). Female-specific increases in body and femur length and female-specific decreases in expressions of components of IGF1 ternary complexes (IGF1 and IGFBP5 in plasma, and Igfbp3 and Igfals in liver) could be consistent with increased IGF1 availability and signaling in target tissues. Female-specific modulation of key sensors of liver IGF1 signaling pathways (reduced phosphorylation of AKT and ERK2, and increased phosphorylation of AMPKα) may be relevant to explain growth improvement through a regulated IGF1 system by rhPAPP-A2 treatment

Article Snippet: Recombinant human GH protein (rhGH; cat no: ABIN803848; antibodies-online GmbH, Aachen, Germany), recombinant human IGF1 protein (rhIGF1; cat. no: 100 − 11; PeproTech, Inc., Rocky Hill, NJ, USA), and recombinant human PAPP-A2 protein (rhPAPP-A2; cat. no: abx068418; Abbexa LTD, Cambridge; UK) were dissolved in sterile saline (0.9% NaCl).

Techniques: Clinical Proteomics, Protein-Protein interactions, Phospho-proteomics